Aichi, Japan

Haruka Kawaguchi

This inventor holds 1 USPTO granted patent. Top assignee: Ajinomoto Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Haruka Kawaguchi. Retrieved from https://idiyas.com/inventor/haruka-kawaguchi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Haruka Kawaguchi: Innovator in RNA Silencing

Introduction

Haruka Kawaguchi is a notable inventor based in Aichi, Japan. He has made significant contributions to the field of biotechnology, particularly in RNA silencing techniques. His innovative work has garnered attention in the scientific community.

Latest Patents

Kawaguchi holds a patent for a "Method for Inducing RNA Silencing." This patent represents a crucial advancement in the understanding and application of RNA technology. It highlights his commitment to pushing the boundaries of scientific research.

Career Highlights

Kawaguchi is currently employed at Ajinomoto Co., Ltd., a leading company in the food and biotechnology sectors. His role at Ajinomoto allows him to apply his expertise in a practical setting, contributing to the company's innovative projects.

Collaborations

He collaborates with talented coworkers, including Mayu Nakano and Hisashi Yasueda. These partnerships enhance the research environment and foster creativity in their projects.

Conclusion

Haruka Kawaguchi is a pioneering inventor whose work in RNA silencing is shaping the future of biotechnology. His contributions at Ajinomoto Co., Ltd. and collaborations with esteemed colleagues underscore his impact in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…